Condition: Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer · Sponsor: Merck Sharp & Dohme LLC
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham ( Site 0006) | Birmingham, Alabama, United States | Recruiting |
| Alaska Women's Cancer Care ( Site 0096) | Anchorage, Alaska, United States | Recruiting |
| UCSF Medical Center at Mission Bay ( Site 0013) | San Francisco, California, United States | Recruiting |
| John Muir Health Cancer Center ( Site 0016) | Walnut Creek, California, United States | Recruiting |
| Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0001) | New Haven, Connecticut, United States | Recruiting |
| Mount Sinai Braman Comprehensive Cancer Center ( Site 0078) | Miami Beach, Florida, United States | Recruiting |
| Sarasota Memorial Hospital ( Site 0075) | Sarasota, Florida, United States | Recruiting |
| Florida Cancer Specialists East ( Site 7000) | West Palm Beach, Florida, United States | Recruiting |
| Winship Cancer Institute of Emory University ( Site 0086) | Atlanta, Georgia, United States | Recruiting |
| Augusta University - Georgia Cancer Center ( Site 0066) | Augusta, Georgia, United States | Recruiting |
| Parkview Research Center at Parkview Regional Medical Center ( Site 0003) | Fort Wayne, Indiana, United States | Recruiting |
| Women's Cancer Care ( Site 0067) | Covington, Louisiana, United States | Recruiting |
+ 174 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06824467